CDC Open Call to Industry – Influenza A(H5) Diagnostic Test Development and Validation

The Centers for Disease Control and Prevention (CDC) is initiating an open call for innovative solutions to meet the CDC's diagnostic test development needs.

This open Call to Industry is considered to have high potential for one or more agreements that may be accomplished via CDC's Other Transaction (OT) authority pursuant to 42 USC 242c. As such, assessment activities conducted in furtherance of an award or awards are considered competitive in the same manner as a Broad Agency Announcement (BAA) or Commercial Solutions Opening (CSO), and solutions will be assessed independently of one another primarily for technical merit. The procedures outlined in this open call are considered by CDC to satisfy the reasonable effort to obtain competition.

Solution Providers shall submit concept papers via email to mcrow@cdc.gov no later than 11:59 PM Eastern on Wednesday, June 26th, 2024 in order to be considered for further evaluation. The government does not anticipate the ability to consider late concept paper submissions.

Solution Providers are instructed to contact ONLY the CDC Office of Acquisition Services point(s) of contact notated in this announcement. Refer to the attachment(s) to this announcement for full details and instructions.

06/24/2024 Amendment: A Q&A document is provided which contains the government's responses to questions received from potential solutions providers. The deadline for concept paper submission is extended until 11:59 PM Eastern on Wednesday, June 26th, 2024.